Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Novavax Vaccine Prospects Take BioNTech, Moderna Shares Down  

Published 06/14/2021, 11:03 AM
Updated 06/14/2021, 11:04 AM
© Reuters

© Reuters

By Dhirendra Tripathi

Investing.com – Shares of Covid-19 vaccine makers like BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA) weakened on Monday on prospects of one more rival, Novavax (NASDAQ:NVAX), joining them in the market.

BioNTech slumped 9% and Moderna by 8%. Pfizer (NYSE:PFE), which makes and markets the vaccine in collaboration with BioNTech, fell 1.5%.

Johnson & Johnson (NYSE:JNJ), the only one with a single-dose vaccine, was down 0.5%. Novavax itself had a volatile session, giving up its gains of over 9% premarket to go into the red in the session underway.

The company today, in a premarket release, said a phase-three trial had found its two-dose Covid-19 vaccine to be 90.4% effective.

The trial had 29,960 participants across the U.S. and Mexico.

The vaccine was found to be 100% effective in preventing moderate and severe infections and 93% effective against some variants, Novavax said. The company plans to file for approval with the Food and Drug Administration in the third quarter.

Upon regulatory approvals, Novavax remains on track to reach manufacturing capacity of 100 million doses per month by the end of the third quarter and 150 million doses per month by the end of the fourth quarter of 2021, the company said in the release.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.